RxDoctor Payments Data

Maria Bernal, MD

Ophthalmology · Bogalusa, LANPI 1629267893

Payments from drug & device makers

$2,645in general payments, 2019–2025

Across 95 payments — averaging $27.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$501
  • AbbVie$383
  • Tarsus Pharmaceuticals, Inc.$359
  • Oyster Point Pharma, Inc.$255
  • Sun Pharmaceutical Industries Inc.$173
  • Dompe US, Inc.$143
  • plus $831 from 15 others

What the payments were for

  • Food & beverage$2,645100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,645 in reported general payments places this provider in the 55th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$61,389
Medicare patients
230
Services billed
618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine120$92,098
XiidraLifitegrast44$41,591
TyrvayaVarenicline Tartrate36$32,689
XdemvyLotilaner14$26,617
IlevroNepafenac63$23,861
MieboPerfluorohexyloctane/Pf17$19,972
ProlensaBromfenac Sodium25$10,965
Cyclosporine35$10,787
Prednisolone Acetate242$10,554
Alphagan PBrimonidine Tartrate21$7,771
LumiganBimatoprost15$7,057
ValacyclovirValacyclovir Hcl109$6,063
Difluprednate53$5,985
CombiganBrimonidine Tartrate/Timolol17$5,293
SimbrinzaBrinzolamide/Brimonidine Tart16$4,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P, Lumigan, Combigan$383$112,219173 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$121$61,56361 claims
Oyster Point Pharma, Inc.Tyrvaya$255$32,68936 claims
NovartisIlevro, Durezol$114$26,83076 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$359$26,61714 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$100$12,64139 claims
AlconSimbrinza$501$4,59416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in Bogalusa

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →